Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.44 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL81910 | 0.95 | PTAFR (0.50) | PTAFRALDH1A1LMNANAMPTCYP3A4 | |
| SCHEMBL82837 | 0.95 | PTAFR (0.53) | PTAFRALDH1A1LMNANAMPTTBXAS1 | |
| SCHEMBL81394 | 0.94 | PTAFR (0.49) | PTAFRALDH1A1LMNANAMPTCYP3A4 | |
| SCHEMBL82430 | 0.94 | PTAFR (0.49) | PTAFRALDH1A1LMNANAMPTCYP3A4 | |
| SCHEMBL3079286 | 0.93 | PTAFR (0.48) | PTAFRALDH1A1LMNANAMPTCYP3A4 | |
| SCHEMBL83930 | 0.92 | LMNA (0.49) | PTAFRALDH1A1LMNACYP3A4CYP2C9 | |
| SCHEMBL5557428 | 0.90 | DRD2 (0.48) | PTAFRALDH1A1LMNACYP3A4CYP2C9 | |
| SCHEMBL5557508 | 0.88 | NAMPT (0.47) | PTAFRALDH1A1LMNANAMPTCYP3A4 | |
| SCHEMBL83847 | 0.88 | LMNA (0.51) | PTAFRALDH1A1LMNACYP3A4CYP2C9 | |
| SCHEMBL3080363 | 0.83 | NAMPT (0.45) | NAMPTCYP3A4CYP2C9C3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4607319-B2 | — | — | 2011-01-05 | — | — | JP | claimed |
| JP-4599062-B2 | — | — | 2010-12-15 | — | — | JP | claimed |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-09-09 | — | — | US | claimed |
| EP-1487444-B9 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-07-21 | — | — | EP | claimed |
| EP-1487444-B1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2009-12-30 | — | — | EP | claimed |
| US-20060052419-A1 | Use of pyridly amides as inhibitors of angiogenesis | ASTELLAS DEUTSCHLAND GMBH (DE) | 2006-03-09 | — | — | US | claimed |
| EP-1079832-B1 | USE OF VITAMIN PP COMPOUNDS | KLINGE CO CHEM PHARM FAB (DE) | 2005-11-30 | — | — | EP | claimed |
| JP-2005528361-A | — | — | 2005-09-22 | — | — | JP | claimed |
| EP-1487444-A1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | Fujisawa Deutschland GmbH (DE) | 2004-12-22 | — | — | EP | claimed |
| US-20040176605-A1 | New pyridyl alkane acid amides as cytostatics and immunosuppressives | KLINGE PHARMA GMBH | 2004-09-09 | — | — | US | claimed |
| WO-2003080054-A1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | FUJISAWA DEUTSCHLAND GMBH (DE) | 2003-10-02 | — | — | WO | claimed |
| EP-1348434-A1 | Use of pyridyl amides as inhibitors of angiogenesis | Fujisawa Deutschland GmbH (DE) | 2003-10-01 | — | — | EP | claimed |
| US-20030162972-A1 | Pyridyl alkane acid amides as cytostatics and immunosupressives | KLINGE PHARMA GMBH | 2003-08-28 | — | — | US | claimed |
| EP-0934309-B1 | NEW PYRIDYL ALKANE ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | FUJISAWA DEUTSCHLAND GMBH (DE) | 2002-09-11 | — | — | EP | claimed |
| US-6444823-B1 | ANTITUMOR AGENTS; IMMUNOSUPPRESSANTS; SIDE EFFECT REDUCTION | KLINGE PHARMA GMBH (DE) | 2002-09-03 | — | — | US | claimed |
| EP-1228044-A2 | PYRROLO IMIDAZOLE DERIVATIVES AND THEIR USE AS MEDICAMENTS | Morphochem AG (DE) | 2002-08-07 | — | — | EP | claimed |
| JP-2002512190-A | — | — | 2002-04-23 | — | — | JP | claimed |
| WO-2001025213-A2 | PYRROLO IMIDAZOLE DERIVATIVES AND THEIR USE AS MEDICAMENTS | MORPHOCHEM AG (DE) | 2001-04-12 | — | — | WO | claimed |
| EP-1079832-A1 | USE OF VITAMIN PP COMPOUNDS | Klinge Pharma GmbH (DE) | 2001-03-07 | — | — | EP | claimed |
| WO-1999053920-A1 | USE OF VITAMIN PP COMPOUNDS | KLINGE PHARMA GMBH (DE) | 1999-10-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176605-A1 | New pyridyl alkane acid amides as cytostatics and immunosuppressives | ALK, ANXA1, ANXA11 | PTAFR 686/4885ALDH1A1 216/4885LMNA 4352/4885 |
| US-20060052419-A1 | Use of pyridly amides as inhibitors of angiogenesis | FLT1, VEGFA, FLT4 | PTAFR 47/4885ALDH1A1 689/4885LMNA 3601/4885 |
| US-20030162972-A1 | Pyridyl alkane acid amides as cytostatics and immunosupressives | ALK, TYMP, ANXA1 | PTAFR 768/4885ALDH1A1 168/4885LMNA 4311/4885 |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | PNPO, NAMPT, NAPRT | PTAFR 1637/4885ALDH1A1 1385/4885LMNA 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.